+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Susan G. Komen Career Catalyst Research (CCR) Grants

Susan G. Komen Breast Cancer Foundation

Susan G. Komen Career Catalyst Research (CCR) Grants Key Dates:

Letter of Intent (LOI) Announcement: May 28, 2026
Institution Opt-in Deadline: June 10, 2026
Letter of Intent Due: July 29, 2026, by 1 pm, ET
Letter of Intent Decision: August 17, 2026
Application Due: October 5, 2026, by 1 pm, ET

About the Grant: Susan G. Komen Career Catalyst Research (CCR) Grants foster promising breast cancer researchers who are in the early stages of their faculty careers by providing support for up to three years of “protected time” for research career development under the guidance of a Mentor Committee. We seek to support those who will emerge as the next key leaders in the fight against breast cancer.

CCR Grant Terms: Applicant/Primary Investigator (PI) may request funding of up to $150,000 per year (combined direct and indirect costs) for up to three years ($450,000).

CCR Limited Submission Nomination Process: Institutions must respond to missiongrantsadmin@komen.org by June 10, 2026, to indicate that they are opting in to the institutional nomination process. This is a limited submission opportunity: each institution may submit up to two nominees to apply for this funding. Applicant/PI cannot self-nominate. The Institution’s Office of Sponsored Programs, Grants Office, or equivalent must select the nominees to apply for this funding.

Prior to the LOI submission deadline (July 29, 2026), institutions that have opted in must provide Komen with the names and email addresses of the two applicants (based on eligibility requirements) being nominated to apply for funding. Institutions will receive a link that their nominees may use to submit the required documents for LOI submission.

CCR Research Focus: Research projects must be hypothesis-driven, breast cancer-focused studies. They may be considered basic, translational, clinical and/or population science in nature and should align with Komen’s research priorities and mission to save lives from breast cancer.

AI Based Application Success Predictor

1. Direct relevance to breast cancer (Highest Predictor ⭐⭐⭐⭐⭐)

This is the most important success factor.

Competitive proposals should focus specifically on breast cancer, including:

Breast cancer biology
Triple-negative breast cancer (TNBC)
HER2-positive breast cancer
Hormone receptor-positive breast cancer
Metastatic breast cancer
Breast cancer prevention
Early detection
Biomarkers
Precision oncology
Survivorship
Breast cancer disparities
Implementation science

Projects without a clear breast cancer focus are generally not competitive.

2. Strong potential to reduce breast cancer mortality and improve patient outcomes (Highest Predictor ⭐⭐⭐⭐⭐)

Susan G. Komen's mission is to save lives by ending breast cancer.

Competitive proposals should demonstrate potential to:

Reduce mortality
Improve survival
Improve early detection
Enhance treatment effectiveness
Reduce recurrence
Improve quality of life
Improve survivorship care

Projects with a clear pathway to meaningful patient benefit receive the strongest consideration.

3. Scientific excellence and significance (Highest Predictor ⭐⭐⭐⭐⭐)

Reviewers evaluate:

Importance of the research question
Scientific significance
Biological or clinical rationale
Potential to advance breast cancer research

Competitive proposals should address important unmet needs with high scientific quality.

4. Innovation and originality (Very High Predictor ⭐⭐⭐⭐⭐)

Competitive projects often investigate:

Novel therapeutic targets
Immunotherapy
AI and digital pathology
Biomarker discovery
Precision medicine
Liquid biopsy
Early detection technologies
Novel clinical trial designs
New implementation strategies

Incremental research is generally less competitive than transformative approaches.

5. Strong translational potential (Very High Predictor ⭐⭐⭐⭐⭐)

Komen strongly supports research that moves discoveries toward patient care.

Competitive proposals often include:

Translational research
Clinical trials
Biomarker validation
Drug development
Precision oncology
Implementation science
Clinical decision-support tools

Even basic science proposals should describe a realistic path to clinical application.

6. Rigorous methodology and feasibility (Very High Predictor ⭐⭐⭐⭐⭐)

Competitive applications should include:

Clear hypotheses
Appropriate study design
Robust statistical analysis
Well-defined endpoints
Feasible milestones
Risk management strategies

Reviewers expect technically rigorous and achievable research plans.

7. Addressing breast cancer disparities and health equity (Very High & Distinctive Predictor ⭐⭐⭐⭐⭐)

A defining feature of Susan G. Komen funding is its emphasis on health equity.

Competitive proposals may address:

Racial and ethnic disparities
Rural populations
Medically underserved communities
Socioeconomic barriers
Access to screening
Access to treatment
Social determinants of health

Projects that reduce inequities in breast cancer outcomes align closely with Komen's strategic priorities.

8. Outstanding investigator and career development (High Predictor ⭐⭐⭐⭐☆)

For Career Catalyst and Career Transition Awards, reviewers evaluate:

Publication record
Scientific independence
Leadership potential
Long-term commitment to breast cancer research
Career trajectory

Early-career investigator development is a major goal of several Komen funding mechanisms.

9. Strong research environment and mentorship (High Predictor ⭐⭐⭐⭐☆)

Competitive applications benefit from:

Outstanding institution
Experienced mentors
Protected research time
Access to clinical and laboratory infrastructure
Multidisciplinary collaborations

For career-development awards, mentorship quality is a significant review criterion.

10. Patient engagement and community relevance (High Predictor ⭐⭐⭐⭐☆)

Susan G. Komen places strong emphasis on the voice of patients and advocates.

Competitive proposals may include:

Patient advisory groups
Community engagement
Patient-centered outcomes
Dissemination to advocacy organizations
Stakeholder involvement

Research with meaningful patient engagement is particularly valued, especially for implementation and survivorship studies.

Specialties

Cancer

Oncology

Gynecology

Eligibility Requirements

Applicant/PI must currently hold a full-time faculty appointment or have a formal offer letter from the Institution that confirms their position and start date by the Application due date (October 5, 2026). Applicants/PIs must not have held any faculty appointment, including non-tenure and tenure track appointments combined, for more than a total of 6 years by the Application due date (October 5, 2026).

Sponsor Details

Sponsor Institute/Organizations: Susan G. Komen Breast Cancer Foundation

Sponsor Type: Corporate/Non-Profit

Address: 13770 Noel Road, Suite 801889, Dallas, TX 75380

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity